Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth.
about
Use of biochemical tests of placental function for improving pregnancy outcomeUse of biochemical tests of placental function for improving pregnancy outcomeLow-molecular weight heparin increases circulating sFlt-1 levels and enhances urinary eliminationDelivery of a small for gestational age infant and greater maternal risk of ischemic heart disease.Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial.Do anti-angiogenic or angiogenic factors contribute to the protection of birth weight at high altitude afforded by Andean ancestry?Obstetric antiphospholipid syndrome: early variations of angiogenic factors are associated with adverse outcomes.Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery.Serum concentrations of soluble Flt-1 are decreased among women with a viable fetus and no symptoms of miscarriage destined for pregnancy loss.The vascular endothelial growth factor family in adverse pregnancy outcomes.An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study.Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice.First trimester PAPP-A levels correlate with sFlt-1 levels longitudinally in pregnant women with and without preeclampsia.Soluble Flt-1 and PlGF: new markers of early pregnancy loss?Angiogenic factors and preeclampsia.Midpregnancy levels of angiogenic markers in relation to maternal characteristics.Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review.Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsiaPrediction of Fetal Growth Restriction by Analyzing the Messenger RNAs of Angiogenic Factor in the Plasma of Pregnant Women.Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.Air pollution exposure and markers of placental growth and function: the generation R study.Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia?Midgestation maternal serum 25-hydroxyvitamin D level and soluble fms-like tyrosine kinase 1/placental growth factor ratio as predictors of severe preeclampsiaThe effect of maternal soluble FMS-like tyrosine kinase 1 during pregnancy on risk of preterm deliveryThe role of angiogenic, anti-angiogenic and vasoactive factors in pre-eclamptic African women: early- versus late-onset pre-eclampsiaAn Elevated Maternal Plasma Soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio at Midtrimester Is a Useful Predictor for PreeclampsiaThe interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia.Low VEGF expression in conceptus material and maternal serum AFP and β-hCG levels as indicators of defective angiogenesis in first-trimester miscarriagesEvidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death.Maternal serum placental growth factor and pregnancy-associated plasma protein A measured in the first trimester as parameters of subsequent pre-eclampsia and small-for-gestational-age infants: A prospective observational studyOptions and decision-making: hypertensive disorders of pregnancy.First trimester screening can predict adverse pregnancy outcomes.Angiogenic biomarkers in pregnancy: defining maternal and fetal health.Midterm eGFR and Adverse Pregnancy Outcomes: The Clinical Significance of Gestational Hyperfiltration.Preterm Delivery as a Unique Pathophysiologic State Characterized by Maternal Soluble FMS-Like Tyrosine Kinase 1 and Uterine Artery Resistance During Pregnancy.Early Pregnancy Biochemical Predictors of Gestational Diabetes Mellitus.Anti-angiogenesis and Preeclampsia in 2016.Circulating free soluble fms-like tyrosine kinase-1 during late first trimester in relation with placental volume as a surrogate for trophoblastic production: a physiology study in low-risk cohort.Prediction of preeclampsia with angiogenic biomarkers. Results from the prospective Odense Child Cohort.
P2860
Q24187645-4069BA31-5224-4EFD-B4DB-8FEA9A7EC7A0Q24194995-6F336380-2593-44BC-BB89-EE04E21ED1BEQ28538906-9B9B1C6B-ACEF-414A-9CB7-30D3F0CAFA80Q31052158-ED7D403F-BC33-4EF5-B116-467BD47FDCB1Q33382169-8708FD3B-B508-4C57-AC00-E0ED808F0822Q33624964-10638199-8657-4D69-A688-2FC66CB4565AQ33815975-6DDB1903-C5D1-400E-9680-B244F90213BDQ33863973-2485C908-49EE-41D9-8225-0774D2F6DB8CQ34116772-D1BCA63A-7F35-42FC-AA0D-CE41D609FBB1Q34184588-0F9FEC68-6E67-493A-8963-E7D33E4F2F2CQ34267491-4DA7EB15-6BF2-4499-82F0-43F95416F59CQ34505090-07D87B46-7218-41EB-92FE-B9221AA82A7AQ34517776-66584E7B-E765-445E-88FE-3CA257583C84Q34655258-A7E483A1-499E-4CD6-8C24-2DCDCB12D6DEQ34712652-A93196B4-7C52-473A-8FFE-2759A4190855Q34714082-CBBED04C-5665-4E61-8AD1-A7D649C38CD5Q34821237-E199EFE3-7166-4E9B-81CF-2492377AB6D3Q35136184-D2E22F77-A4E2-44F9-802B-3159088C62D0Q35754194-58D9DC54-25C5-4EDF-ABCE-EC1F300235EFQ35853166-71E1495A-7CC3-459E-A437-2C8732CC5FC8Q36062460-DA7DD104-D220-4DDB-AAF9-B0A937F0CFDDQ36543115-522E6ACD-5349-47B0-9B67-5D84A857BFF9Q36626307-CCC4332A-9B6E-4758-865D-88E28D3F75CEQ36694041-A2B168CD-0DA3-4905-89D2-2DDAFDB28D6EQ36784270-4D8B9DFD-48F0-4270-AA9F-1FB10E8192CEQ37041658-5A2C7483-6CA5-4BD7-84FA-1E7B8EE5932EQ37400597-11B6E3AC-5C3D-4670-8533-961D88464270Q37607698-4BF6F216-85B9-4BBF-919E-102C469014EDQ37611132-6BF7A1BA-64A8-4A68-8916-3A7DA5EA98F3Q37612429-C4E94251-347B-4343-B148-CBF36BFD02BBQ37718889-97DEE78C-584E-4B6B-A776-318949D9C4C3Q37770575-84E324C8-F25A-4E63-ABDA-87AC233468DCQ38210332-0319110B-1EDD-4242-94E5-EB12C5298F13Q38370968-46A1C34C-7157-4610-9DAF-A9B268BD01E2Q38727068-55DC387C-6F4E-4B21-861D-E1BD23119DF2Q38881770-C960C5E3-D7E8-4B41-918E-92CBA0DD3CC8Q38946988-62AF6F93-1FA3-4C9B-A427-275C037BD41EQ39117000-56FE012D-A5FB-4EB5-89E6-4B5F9A8B944DQ39394557-98FAA14A-FB3D-437D-96EB-25CF7860DF3AQ39783174-FD47EEF4-9FAF-47B8-8418-6809BB5A1B59
P2860
Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Circulating angiogenic factors ...... preterm birth, and stillbirth.
@en
Circulating angiogenic factors ...... preterm birth, and stillbirth.
@nl
type
label
Circulating angiogenic factors ...... preterm birth, and stillbirth.
@en
Circulating angiogenic factors ...... preterm birth, and stillbirth.
@nl
prefLabel
Circulating angiogenic factors ...... preterm birth, and stillbirth.
@en
Circulating angiogenic factors ...... preterm birth, and stillbirth.
@nl
P2093
P1476
Circulating angiogenic factors ...... preterm birth, and stillbirth.
@en
P2093
Alan D Cameron
David A Aitken
Fiona Lyall
Gordon C S Smith
J Michael Connor
Jennifer A Crossley
Nicola Jenkins
Richard Dobbie
P304
P356
10.1097/01.AOG.0000265804.09161.0D
P407
P577
2007-06-01T00:00:00Z